Introducing Kyfora Bio — Polysciences' bioprocessing brand, supporting development of cell and gene therapy.

USA Manufacturing: With manufacturing facilities located only in the US, we help minimize the risk of tariff-related delays and surcharges.

DODAP (1,2-dioleoyl-3-dimethylammonium propane)

DODAP (1,2 - dioleoyl - 3 - dimethylammonium propane) - Polysciences

DODAP (1,2 - dioleoyl - 3 - dimethylammonium propane) - Polysciences

Product Number:

CAS #

14489

127512-29-2

Product #

CAS #

14489

127512-29-2

Now offered by Kyfora Bio, a Polysciences affiliate. Order at KyforaBio.com.

Product Specifications

No Product Specifications

Safety Data Sheet (SDS)

Related Documents

No Related Documents

References

Fattore, L., Campani, V., Ruggiero, C.F., Salvati, V., Liguoro, D., Scotti, L., Botti, G., Ascierto, P.A., Mancini, R., De Rosa, G., Ciliberto, G. (2020). In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Int J Mol Sci. 12;21(6):1930.

Granot, Y., & Peer, D. (2017). Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin Immunol. 34:68-77.

Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D. (2018). mRNA vaccines -- a new era in vaccinology. Nat. Rev. Drug Discov. 17:261 -279.

Herrington, T., Patlolla, R., & Altin, J. (2009). Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J. Gene Med. 11(11): 1048-63.

Sahin, U., Karikó, K., Türeci, Ö. (2014). mRNA-based therapeutics -- developing a new class of drugs. Nat. Rev. Drug Discov. 13:759 -780.

Semple, S., Klimuk, S., Harasym, T., Dos Santos, N., Ansell, S., Wong, K., Maurer, N., Stark, H., Cullis, P., Hope, M., & Scherrer, P. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochemimica et Biophysica Acta. 1510(1-2): 152-166.

Visit KyforaBio.com to purchase

Product Description

Key Features

High transfection efficiency and low cytotoxicity
Efficient delivery of plasmid DNA, siRNA/miRNA, and CRISPR/Cas9 components
Widely used in nanomedicine
Flexible and scalable

DODAP (1,2-dioleoyl-3-dimethylammonium-propane) is an ionizable cationic lipid with lower cytotoxicity and high transfection efficiency. DODAP is neutral at physiological pH, but acquires a positive charge inside the endosome due to the protonation of free amines when pH is lower than its pKa (<7). The electrostatic interactions between DODAP and naturally occurring anionic lipids in endosomal membranes trigger the release of nucleic acid. These interactions promote membrane lytic non-bilayer structures to enable the intracellular delivery of nucleic acid. A common application is in nanomedicine as an ionizable lipid component of nanocarriers (lipid-polymer hybrid nanoparticles, LPNs), widely used to encapsulate bioactive molecules, including mRNA, siRNA, and plasmid DNA as a treatment for diseases.

DODAP (1,2 - dioleoyl - 3 - dimethylammonium propane) - Polysciences

DODAP (1,2 - dioleoyl - 3 - dimethylammonium propane) - Polysciences

Product Specifications

No Product Specifications

Appearance

Colorless to light yellow liquid

Application

DNA, SiRNA, mRNA transfection, Drug delivery, Gene therapy

Safety Data Sheet (SDS)

-20°C

Related Documents

References

Fattore, L., Campani, V., Ruggiero, C.F., Salvati, V., Liguoro, D., Scotti, L., Botti, G., Ascierto, P.A., Mancini, R., De Rosa, G., Ciliberto, G. (2020). In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Int J Mol Sci. 12;21(6):1930.

Granot, Y., & Peer, D. (2017). Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint. Semin Immunol. 34:68-77.

Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D. (2018). mRNA vaccines -- a new era in vaccinology. Nat. Rev. Drug Discov. 17:261 -279.

Herrington, T., Patlolla, R., & Altin, J. (2009). Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J. Gene Med. 11(11): 1048-63.

Sahin, U., Karikó, K., Türeci, Ö. (2014). mRNA-based therapeutics -- developing a new class of drugs. Nat. Rev. Drug Discov. 13:759 -780.

Semple, S., Klimuk, S., Harasym, T., Dos Santos, N., Ansell, S., Wong, K., Maurer, N., Stark, H., Cullis, P., Hope, M., & Scherrer, P. (2001). Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochemimica et Biophysica Acta. 1510(1-2): 152-166.